Valneva's 15min chart sees KDJ Golden Cross, Bullish Marubozu trend.

Valneva's 15-minute chart has triggered a significant technical indicator, the KDJ Golden Cross, accompanied by a bullish Marubozu at 10:10 on October 10th, 2025. This signals a shift in the momentum of the stock price towards the upside, with potential for further growth. The control of the market is now in the hands of buyers, and it is likely that bullish momentum will continue.

Valneva SE (NASDAQ: VALN), a biotechnology company specializing in vaccines, has revised its 2025 financial outlook due to the U.S. FDA's August decision to revoke the marketing authorization for its chikungunya vaccine Ixchiq over safety concerns. The company has now projected full-year sales to be €155M-€170M, down from the previously anticipated €170-€180M, and revenue to be €165M-€180M, down from the earlier forecast of €180M-€190M Valneva lowers 2025 financial outlook due to loss of Ixchiq vaccine marketing^[1].

In response to the regulatory setback, Valneva entered into a debt facility of up to $500M with funds managed by Pharmakon Advisors. The initial tranche of $215M will be used to pay off an existing debt facility with Deerfield Management Company and OrbiMed, while the remaining up to $285M can be drawn in the future for business development.

Despite the setback, Valneva remains optimistic about its pipeline. The phase 3 trial of its Lyme disease vaccine asset is on schedule, and partner Pfizer (PFE) is expected to submit a Biologics License Application to the FDA and a Marketing Authorization Application to the European Medicines Agency in 2026, assuming positive phase 3 data.

On a separate note, Valneva's stock price has shown a significant technical indicator, the KDJ Golden Cross, accompanied by a bullish Marubozu at 10:10 on October 10th, 2025. This signals a shift in the momentum of the stock price towards the upside, with potential for further growth. The control of the market is now in the hands of buyers, and it is likely that bullish momentum will continue .